Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Investors can access the webcast through Liquidia's website, and a replay will be available for one year.
Liquidia Corporation (NASDAQ: LQDA), un'azienda biofarmaceutica specializzata in terapie per malattie cardiopolmonari rare, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per giovedì 8 maggio 2025. La società terrà una webcast alle 8:30 a.m. ora orientale per discutere i risultati finanziari e fornire un aggiornamento aziendale. Gli investitori potranno accedere alla webcast tramite il sito web di Liquidia, e la registrazione sarà disponibile per un anno.
Liquidia Corporation (NASDAQ: LQDA), una compañía biofarmacéutica enfocada en terapias para enfermedades cardiopulmonares raras, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el jueves 8 de mayo de 2025. La empresa realizará una transmisión en vivo a las 8:30 a.m. hora del Este para discutir los resultados financieros y ofrecer una actualización corporativa. Los inversionistas podrán acceder a la transmisión a través del sitio web de Liquidia, y una repetición estará disponible durante un año.
Liquidia Corporation (NASDAQ: LQDA)는 희귀 심폐 질환 치료제에 주력하는 바이오제약 회사로, 2025년 1분기 재무 결과 발표를 2025년 5월 8일 목요일로 예정했습니다. 회사는 동부 표준시 오전 8시 30분에 웹캐스트를 진행하여 재무 결과를 설명하고 회사 현황을 업데이트할 예정입니다. 투자자들은 Liquidia 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 재방송은 1년간 제공됩니다.
Liquidia Corporation (NASDAQ : LQDA), une société biopharmaceutique spécialisée dans les thérapies pour les maladies cardiopulmonaires rares, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le jeudi 8 mai 2025. L'entreprise organisera un webcast à 8h30, heure de l'Est pour discuter des résultats financiers et fournir une mise à jour d'entreprise. Les investisseurs pourront accéder au webcast via le site web de Liquidia, et un replay sera disponible pendant un an.
Liquidia Corporation (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene kardiopulmonale Erkrankungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Donnerstag, den 8. Mai 2025 geplant. Das Unternehmen wird um 8:30 Uhr Eastern Time eine Webkonferenz veranstalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können über die Website von Liquidia auf die Webkonferenz zugreifen, und eine Aufzeichnung wird ein Jahr lang verfügbar sein.
- None.
- None.
MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When will Liquidia (LQDA) report Q1 2025 earnings?
What time is Liquidia's Q1 2025 earnings call?
How can I access Liquidia's Q1 2025 earnings webcast?
How long will Liquidia's Q1 2025 earnings webcast be available for replay?
